5x8l - Revision history

OCA at 07:29, 7 October 2020

OCA — Wed, 07 Oct 2020 07:29:24 GMT

←Older revision		Revision as of 07:29, 7 October 2020
Line 1:		Line 1:

	==PD-L1 in complex with atezolizumab==		==PD-L1 in complex with atezolizumab==
-	<StructureSection load='5x8l' size='340' side='right' caption='[[5x8l]], [[Resolution\|resolution]] 3.10Å' scene=''>	+	<StructureSection load='5x8l' size='340' side='right'caption='[[5x8l]], [[Resolution\|resolution]] 3.10Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[5x8l]] is a 15 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5X8L OCA]. For a <b>guided tour on the structure components</b> use [http://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=5X8L FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[5x8l]] is a 15 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5X8L OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=5X8L FirstGlance]. <br>
	</td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5x8m\|5x8m]]</td></tr>		</td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5x8m\|5x8m]]</td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=5x8l FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5x8l OCA], [http://pdbe.org/5x8l PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5x8l RCSB], [http://www.ebi.ac.uk/pdbsum/5x8l PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5x8l ProSAT]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=5x8l FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5x8l OCA], [http://pdbe.org/5x8l PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5x8l RCSB], [http://www.ebi.ac.uk/pdbsum/5x8l PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5x8l ProSAT]</span></td></tr>
	</table>		</table>
	== Function ==		== Function ==
Line 22:		Line 22:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Large Structures]]
	[[Category: Heo, Y S]]		[[Category: Heo, Y S]]
	[[Category: Lee, H T]]		[[Category: Lee, H T]]

OCA at 05:53, 17 August 2017

OCA — Thu, 17 Aug 2017 05:53:12 GMT

←Older revision		Revision as of 05:53, 17 August 2017
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 5x8l is ~~ON HOLD~~	+	==PD-L1 in complex with atezolizumab==
		+	<StructureSection load='5x8l' size='340' side='right' caption='[[5x8l]], [[Resolution\|resolution]] 3.10Å' scene=''>
		+	== Structural highlights ==
		+	<table><tr><td colspan='2'>[[5x8l]] is a 15 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5X8L OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5X8L FirstGlance]. <br>
		+	</td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5x8m\|5x8m]]</td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5x8l FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5x8l OCA], [http://pdbe.org/5x8l PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5x8l RCSB], [http://www.ebi.ac.uk/pdbsum/5x8l PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5x8l ProSAT]</span></td></tr>
		+	</table>
		+	== Function ==
		+	[[http://www.uniprot.org/uniprot/PD1L1_HUMAN PD1L1_HUMAN]] Involved in the costimulatory signal, essential for T-cell proliferation and production of IL10 and IFNG, in an IL2-dependent and a PDCD1-independent manner. Interaction with PDCD1 inhibits T-cell proliferation and cytokine production.<ref>PMID:10581077</ref> <ref>PMID:11015443</ref>
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	In 2016 and 2017, monoclonal antibodies targeting PD-L1, including atezolizumab, durvalumab, and avelumab, were approved by the FDA for the treatment of multiple advanced cancers. And many other anti-PD-L1 antibodies are under clinical trials. Recently, the crystal structures of PD-L1 in complex with BMS-936559 and avelumab have been determined, revealing details of the antigen-antibody interactions. However, it is still unknown how atezolizumab and durvalumab specifically recognize PD-L1, although this is important for investigating novel binding sites on PD-L1 targeted by other therapeutic antibodies for the design and improvement of anti-PD-L1 agents. Here, we report the crystal structures of PD-L1 in complex with atezolizumab and durvalumab to elucidate the precise epitopes involved and the structural basis for PD-1/PD-L1 blockade by these antibodies. A comprehensive comparison of PD-L1 interactions with anti-PD-L1 antibodies provides a better understanding of the mechanism of PD-L1 blockade as well as new insights into the rational design of improved anti-PD-L1 therapeutics.

-	~~Authors~~:	+	Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab.,Lee HT, Lee JY, Lim H, Lee SH, Moon YJ, Pyo HJ, Ryu SE, Shin W, Heo YS Sci Rep. 2017 Jul 17;7(1):5532. doi: 10.1038/s41598-017-06002-8. PMID:28717238<ref>PMID:28717238</ref>

-	~~Description~~:	+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-	[[Category: ~~Unreleased Structures~~]]	+	</div>
		+	<div class="pdbe-citations 5x8l" style="background-color:#fffaf0;"></div>
		+	== References ==
		+	<references/>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Heo, Y S]]
		+	[[Category: Lee, H T]]
		+	[[Category: Antibody]]
		+	[[Category: Complex]]
		+	[[Category: Immune system]]

OCA: Protected "5x8l" [edit=sysop:move=sysop]

OCA — Thu, 09 Mar 2017 15:54:35 GMT

Protected "5x8l" [edit=sysop:move=sysop]

←Older revision

Revision as of 15:54, 9 March 2017

OCA: New page: '''Unreleased structure''' The entry 5x8l is ON HOLD Authors: Description: Category: Unreleased Structures

OCA — Thu, 09 Mar 2017 15:54:33 GMT

New page: '''Unreleased structure''' The entry 5x8l is ON HOLD Authors: Description: Category: Unreleased Structures

New page

'''Unreleased structure'''

The entry 5x8l is ON HOLD

Authors:

Description:
[[Category: Unreleased Structures]]